Award

Randomized, double-blind, placebo-controlled study to evaluate the effect of metformin, an activator of AMPK, on cognitive decline in patients with Huntington's disease

Description: Huntington disease (HD) is a devastating condition that affects 1-7 every 100.000 Europeans. HD patients carry an abnormally long expansion of CAG triplet, which encodes polyglutamines, in the huntingtin gene. When these expansions are equal to or greater than 36, they cause the loss of the normal function of huntingtin (Htt), which acquires a toxic gain-of-function. Mutant huntingtin (mHtt) also has a tendency to fold incorrectly and starts an aggregation process, which sequesters other proteins and alters even further the function of cells, with particularly devastating effects in striatal neurons and the cortex in the brain. Cellular processes devoted to remove altered proteins and organelles, such as autophagy, are also malfunctioning in HD patients. We have shown that AMPK is a valid druggable target to fight HD in mice models. Metformin-activated AMPK is a potent inductor of autophagy, which in turns removes mHtt aggregates from striatum and cortex in mice, but also reduces neuroinflammation, and raises low levels of BDNF. These molecular changes induce functional recovery of mice (motor impairment and psychiatric function). We have shown that patients of HD, that are also type 2 diabetics and take metformin, show better cognitive function than patients of HD that do not. Here we will conduct a double-blinded clinical trial, controlled by placebo, using metformin as a therapy to treat patients of HD. We will use cognitive tests to test metformin in these patients. We will also follow progression of the study using biological biomarkers such as neurofilament light, which has shown to be a robust indicator of neuronal damage in different neurodegenerative diseases. The clinical trial will be carried out using at least 60 patients (30 per arm). Our statistic calculations have shown that this number of patients will provide enough statistical power to show effect of metformin in HD patients.
Amount: €322,800
Funding type: grant
Start date: 2020-01-01
End date: 2023-12-31
Investigator: Luis Bataller Alberola (lead)
Institution: FUNDACION PARA LA INVESTIGACION DEL HOSPITAL LA FE
Funded outputs count: 1
Funder award ID: ICI19/00014
OpenAlex ID: G5709749915
2025 · Ana Pilar Gómez-Escribano, Gema García-García, et al. · EBioMedicine · 7